Impact of <i>TP53</i> loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients
Peter H. J. Slootbeek, María Victoria Luna-Velez, Bastiaan M. Privé, Maarten J. van der Doelen, Iris S. H. Kloots, Samhita Pamidimarri Naga, Hilde E. Onstenk, James Nagarajah, Harm Westdorp, Inge M. van Oort, Leonie I. Kroeze, J. Schalken, Haiko J. Bloemendal, Niven Mehra
Abstract
loss-of-function may serve as a prognostic factor for PSMA-RLT outcomes in patients with mCRPC.
Topics & Concepts
Prostate cancerMedicineOncologyInternal medicineProgression-free survivalPopulationLoss functionCohortTranscriptomeCancerCancer researchGeneOverall survivalGene expressionBiologyGeneticsEnvironmental healthPhenotypeProstate Cancer Treatment and ResearchUbiquitin and proteasome pathwaysCancer-related Molecular Pathways